Wednesday, January 13, 2021 8:59:38 AM
January 13 -- Titan Medical (NASDAQ:TMDI) announces that it has received a written response from the FDA to its Request for Information regarding the regulatory requirements applicable to its robotically assisted surgical device (RASD), the Enos Robotic Single Access System.
While the FDAs response to the request does not constitute a classification decision, the regulator has indicated that, based on information provided to the agency, the Enos system is appropriate for classification through the De Novo pathway.
Should the FDA grant the De Novo classification request, the Class II device would be cleared to be marketed.
"During the first quarter of 2021, we plan on further communications with the FDA, including filing a Pre-Submission, with the intent of clarifying any requirements for our planned Investigational Device Exemption studies and any potential impact on previously established timelines and forecasted costs, CEO David McNally said.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM